Michele Guida

[Michele Guida @MicheleGuida13]

Well deserved!

[sabino strippoli @StrippoliSabino]

Beyond clinical trials: cemiplimab in frail, elderly, and immunosuppressed patients, and looking for biomarkers able to predict response

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer https://t.co/QQvTQfisZw

[Michele Guida @MicheleGuida13]

Thanks a lot to all members of melanoma Group of #Istitutotumoribari

[sabino strippoli @StrippoliSabino]

Proud to share the latest work published on @jitcancer by the melanoma research group of the IRCCS cancer institute of Bari leaded by @MicheleGuida13 and with the fundamental contribution of Amalia Azzariti, Letizia Porcelli, @SimonaSumma @serrati_s

[Michele Guida @MicheleGuida13]

Proud to share our latest paper in @ESMO_Open. Aiming to shed light on vitiligo like depigmentation in #melanoma patients treated with #immunotherapy checkpoint inhibitors. A collective effort by @ImiItaliano

https://t.co/OizwYGiRm2

[Michele Guida @MicheleGuida13]

@DrDrAprilRose
Published simultaneously a similar retrospective study showing better outcome in NRAS mut.
Different and heterogeneous population (BRAF mut, ocular, mucosal included)?

[Michele Guida @MicheleGuida13]

In this retrospective study comparing two very homogeneous and large melanoma populations (NRAS mut vs BRAF/NRAS wt) we demonstrated no impact of NRAS mut on clinical outcomes with checkpoint inhibitor's immunotherapy https://t.co/vKuNBVjSIE

[Michele Guida @MicheleGuida13]

@Oncoinfo_it @PAscierto Grandi Paolo e Franco!!

[Oncoinfo @Oncoinfo_it]

Presentati ad #IMI19 importanti dati sulle oligoprogressioni nel #melanoma in stadio avanzato.

@PAscierto @istitutotumori @MandalaMario #melsm